Cutaneous melanoma in the era of molecular profiling

The Lancet

Volumn 374, Issue 9687, 2009, Pages 362-365

  Thompson, John F ^a,b   Scolyer, Richard A ^a,b   Kefford, Richard F ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; GENE MUTATION; MELANOMA; METASTASIS; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY;

EID: 67651241055     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61397-0     Document Type: Note

References (18)

1. Melanoma Molecular Mapping Project. Familial melanoma (2009). www.mmmp.org/MMMP/import.mmmp?page=fam_melanoma.mmmp (accessed June 26, 2009).
2. Leachman SA, Carucci J, Kohlmann W, et al. Guidelines for selection of familial melanoma patients for genetic assessment. J Am Acad Dermatol (in press).
3. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
4. Dhomen N., Reis-Filho J.S., da Rocha Dias S., et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15 (2009) 294-303
5. Viros A., Fridlyand J., Bauer J., et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5 (2008) e120
6. Flaherty K., Pusanov I., Sosman J., et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27 suppl (2009) 9000 (abstr).
7. North J.P., Kageshita T., Pinkel D., LeBoit P.E., and Bastian B.C. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol 128 (2008) 2024-2030
8. Balch C.M., Gershenwald J.E., Soong S.-J., Sober A.J., and Kirkwood J. Melanoma staging and classification. In: Balch C.M., Houghton A.N., Sober A.J., Soong S.-J., Atkins M.B., and Thompson J.F. (Eds). Cutaneous melanoma. 5th edn (2009), Quality Medical Publishing, St Louis 65-86
9. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006) 1307-1317
10. Gershenwald J.E., Andtbacka R.H., Prieto V.G., et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26 (2008) 4296-4303
11. Henderson M.A., Burmeister B., Thompson J.F., et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol 27 suppl (2009) LBA9084 (abstr).
12. Australia and New Zealand Melanoma Trials Group. ANZMTG 1-07: whole brain radiotherapy (WBRT) following local treatment of intracranial metastases of melanoma-a randomised phase III trial. http://www.anzmtg.org/content.aspx?page=currtrials (accessed March 25, 2009).
13. Wheatley K., Ives N., Eggermont A., et al., on behalf of International Malignant Melanoma Collaborative Group. Interferon-alpha as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 25 (2007) 8526 (abstr).
14. Eggermont A.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117-126
15. Eggermont A.M. Vaccine trials in melanoma-time for reflection. Nat Rev Clin Oncol 6 (2009) 256-258
16. O'Day S., Webber J., Lebbe C., et al. Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27 suppl (2009) 9033 (abstr).
17. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 13 suppl 4 (2008) 10-15
18. Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26 (2008) 5233-5239